#1 Review of two target “classes” on the mandated list of relevant pediatric molecular targets: 1) targets linked to cell lineage; and 2) targets on normal immune cells and cells in the tumor microenvironment.

#2 Discussion of information pertinent to the potential development of Pediatric Written Requests (PWRs) for two investigational cancer products, ONC201 and CD24Fc.

Pretomanid tablets for oral administration, submitted by The Global Alliance for TB Drug Development, Inc. (TB Alliance), proposed as part of a combination regimen with bedaquiline and linezolid in adults for the treatment of pulmonary extensively drug resistant and treatment-intolerant or non-responsive multidrug-resistant tuberculosis